H3 Dynamics and Hylium Industries Join Forces to Progress Liquid Hydrogen-Electric Flight Capabilities
16.1.2023 18:07:00 EET | Business Wire | Press release
H3 Dynamics and Hylium Industries have joined forces to boost the performance of zero emission hydrogen-electric flight, by combining the strengths of Hylium’s liquid hydrogen storage and liquification solutions, and H3 Dynamics’ distributed hydrogen-electric propulsion nacelles, ultra-light fuel cells, and new hydrogen drone refueling stations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005162/en/
Joint development for transatlantic crossing with ISAE-SUPAERO Toulouse, H3 Dynamics - using HYLIUM Liquid hydrogen storage (Photo: Business Wire)
Moving to liquid hydrogen represents a significant capability leap for small electric-powered unmanned systems. Cryogenic (liquid) hydrogen stores 3 times more energy as compressed gas in the same given volume. This means delivery drones will be able to fly further, mapping and ISR missions could be done on a much bigger scale.
To illustrate the jump in performance, the same 25kg hydrogen-electric propulsion UAV demonstrated by H3 Dynamics last July in France, will be able to fly over 900km with a single fill. With pressurized hydrogen, that range reduces to 400km, which is still 3 times more than a battery-powered equivalent.
“When combined, our global best-in-class solutions achieve the global performance limit for low-altitude electric powered flight” says Taras Wankewycz, CEO H3 Dynamics. “We are proud to be working with Hylium to move hydrogen-electric flight propulsion to the next level”
Now all the various forms of hydogen drones and UAVs powered by H3 Dynamics including hydrogen airships, multi-rotors, vertical take-off and landing (VTOL), have a way to further boost flight durations by another factor of 3 over pressurized hydrogen systems, or a factor of 10 compared to batteries.
H3 Dynamics also recently announced a first hydrogen production, and automated hydrogen refueling mobile station for hydrogen UAV operations. Named H2FIELD the mobile station produces hydrogen from water and delivers compressed hydrogen gas tanks to the operator with little human intervention and no required hydrogen expertise. H3 Dynamics and Hylium’s partnership will upgrade the station so that it can fill liquid hydrogen tanks.
Developed in South Korea, Hylium’s breakthrough technology provides one of the most advanced solutions and has already been proven in a number of applications. South Korea is also leading the development for LH2 standardisation. One local proposal was accepted as a draft standard by a global ISO committee.
Hylium and H3 Dynamics technologies are currently being integrated to attempt a 3,300km crossing of the South Atlantic, in a program led by ISAE SUPAERO Toulouse, one of the world’s leading aerospace engineering schools. H3 Dynamics’ team developed a special fuselage design that can store a small LH2 tank and manage the thermal behavior of all the propulsion sub-systems.
LH2 technology will also be a next step in H3 Dynamics’ hydrogen-electric propulsor nacelles roadmap. A first twin engine cargo drone powered by these self-contained nacelles took off in the sky of Paris during the summer 2022, using 2 compressed hydrogen tanks – one in each nacelle. The goal now will be to switch them out for liquid hydrogen tanks with a lighter construction and a higher fuel capacity.
About H3 Dynamics www.h3dynamics.com
H3 Dynamics is on a mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as hydrogen refueling and airport power solutions. The company has created a unique pathway to de-risk long term hydrogen aviation developments by starting commercially now with small, scalable solutions. H3 Dynamics employs 93 team members from its 3 regional headquarters in Toulouse, Austin and Singapore. It is a member of the Alliance for Zero Emission Aviation under the European Commission, Sustainable Aero Lab, the Lufthansa Cleantech Hub, the Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
About Hylium Industries: http://hylium-industries.com/
HYLIUM INDUSTRIES, INC. was established in 2014 as a Korea Institute of Science and Technology (KIST) venture company. Since then Hylium have been developing the Korea’s first cryogenic liquid hydrogen manufacturing and storage technologies with R&D support from the Korean Government.
Hylium has developed various technologies related to the hydrogen liquefaction system and owns over 20 patents and intellectual property rights, with more patents pending. In 2015 Hylium Industries’ technologies were acknowledged by the Cryogenic Engineering Conference with a Russel B. Scott Memorial Award for the Best Application in Small-Capacity Hydrogen Liquefaction Technology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005162/en/
Contact information
Taras Wankewycz
CEO, H3 Dynamics
taras@h3dynamics.com
www.h3dynamics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom